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Objective(s): To systematically identify the preferred magnetic resonance imaging (MRI) sequences fol-
lowing volunteer imaging on a 1.5 Tesla (T) MR-Linear Accelerator (MR Linac) for future protocol devel-
opment.
Methods: Non-patient volunteers were recruited to a Research and Ethics committee approved prospec-
tive MR-only imaging study on a 1.5T MR Linac system. Volunteers attended 1–3 imaging sessions that
included a combination of mDixon, T1w, T2w sequences using 2-dimensional (2D) and 3-dimensional
(3D) acquisitions. Each sequence was acquired over 2–7 minutes and reviewed by a panel of 3 observers
to evaluate image quality using a visual grading analysis based on a 4-point Likert scale. Sequences were
acquired and modified iteratively until deemed fit for purpose (online image matching or re-planning)
and all observers agreed they were suitable in 3 volunteers.
Results: 26 volunteers underwent 31 imaging sessions of six general anatomical regions. Images were
acquired in one or two of six general anatomical regions: male pelvis (n = 9), female pelvis (n = 4), chest-
wall/breast (n = 5), lung/oesophagus (n = 5), abdomen (n = 3) and head and neck (n = 5). Images were
acquired using a pre-defined exam-card that on average, included six sequences (range 2–10), with a
maximum scan time of approximately one hour. The majority of observers preferred T2-weighted
sequences. The thorax teams were the only groups to prefer T1-weighted imaging.
Conclusions: An iterative process identified sequence agreement in all anatomical regions. These
sequences will now be evaluated in patient volunteers.
Advances in knowledge: This manuscript is the first publication sharing the results of the first systematic
selection of MRI sequences for use in on-board MRI-guided radiotherapy by end-users (therapeutic radio-
graphers and clinical oncologists) in healthy volunteers.
 2019 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy &
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Of the advances in multimodality imaging contributing to the
improved accuracy of the irradiated target volume and organs at
risk, perhaps MRI (magnetic resonance imaging) is the most signif-
icant through the provision of soft-tissue contrasts superior to that
of computed tomography (CT), the ability to monitor and quantifymotion, and capacity for non-invasive functional imaging. The
integration of magnetic resonance imaging (MRI) into radiotherapy
treatment planning was first reported in the mid-1980s [1]. Yet
despite the benefits of MRI, which include superior soft tissue char-
acterisation compared to computed tomography (CT), multi-planar
capabilities, absence of ionizing radiation and capability for non-
invasive functional imaging [2–5], the optimal use of MRI in the
radiotherapy pathway has not been realised. With the clinical
release of MRI-only planning platforms [6–8] and integrated
MRI-radiotherapy systems, [9–12] interest in the seamless integra-
tion of MRI in the radiotherapy pathway has generated momen-
tum. Recently, guidance on the use of MRI in external beam
Table 1
Most commonly acquired/evaluated sequences across all body regions.
Sequence Orientation echo TE (ms) TR (ms) FA (⁰) FOV (mm) Voxel size (mm) Recon voxel (mm) Time (mins) NSA
T1 3D TFE mDixon Axial 2 shortest Shortest 12 420 * 420 * 300 1.1 * 1.1 * 1.1 0.5 5.11 2
T2 3D TSE Axial 1 shortest 1300 90 420 * 420 * 220 1.2 * 1.2 * 0.6 0.5 6.05 2
T2 TSE MV Axial 1 60 1800–6000 90 500 * 500 * 120 1.3 * 1.3 * 3.0 0.7 5.26 1
T1 3D Axial 1 4.5 Shortest 30 320 * 452 * 300 1.8 * 1.8 * 1.0 0.9 3.42 3
T2 3D Axial 1 82 1300 70 400 * 400 * 250 1.2 * 1.2 * 0.6 0.6 6.01 2
T2 TSE MV SPIR Axial 1 100 3121 90 500 * 500 * 120 1.25 * 1.25 * 3.5 0.89 5.18 1
T2 MS mDixon TSE Axial 1 90 3712 90 300 * 457 * 151 0.9 * 1.0 * 4.0 0.6 4.50 2
TFE = Turbo Field Echo, TSE = Turbo Spin Echo, MS = Multi-slice, MV = Multi-vane, FA = flip angle, NSA = number of signal averages, FOV = field of view, TE = time to echo,
TR = time to recovery, Recon = reconstruction, mm = millimetres, mins = minutes.
Table 2
Anatomy evaluated using VGA within each anatomical region imaged and associated treatment site.
Body Region Treatment Site Anatomy Evaluated
Pelvis - female Cervix Cervix, bladder, rectum, femoral heads, large bowel, small bowel, psoas, lymph nodes, sigmoid
colon
Pelvis - male Prostate Prostate, bladder, rectum, seminal vesicles, bowel, femoral heads
Pelvis -male/female Rectum/Bladder Rectum, bladder, prostate/cervix, large bowel, small bowel, femoral heads, iliac vessels, meso-
rectum
Thorax Breast Breast, chest wall (muscle), lungs, heart, supra clavicular nodes, internal mammary nodes, nodal
regions I, II, III, brachial plexus
Lung/oesophagus Lungs, spinal cord, heart, oesophagus, brachial plexus
Abdomen Adult hepatobiliary pancreatic
tumours
Liver, kidneys, aorta, vertebral bodies, pancreas, duodenum, stomach, small bowel
Paediatric hepatobiliary
pancreatic tumours
Liver, kidneys, pancreas, spleen, spinal cord, heart, trachea, brachial tree
Head and neck Oropharynx, brain Brain stem, optic nerves, optic chiasm, spinal cord, parotid gland, submandibular gland, oropharynx
C.L. Eccles et al. / Technical Innovations & Patient Support in Radiation Oncology 12 (2019) 56–63 57radiotherapy planning (EBRT), has been published and highlights
essential technical MRI requirements to enable MR integration into
the radiotherapy pathway [13,14]. These requirements include (1)
the ability to acquire images in the radiotherapy treatment posi-
tion, (2) the ability to resolve geometric distortions over a large
field of view and (3) rapid sequence acquisition and reconstruc-
tions [13,14]. However, agreement on the most appropriate type
of acquisition and weightings for use in radiotherapy planning, in
most tumour types, remains unaddressed. Without consensus on
image interpretation the potential for the introduction of system-
atic errors in inter-observer contouring variations for traditional
EBRT planning pathways remains.
When MRI is used for on-board image guidance or as a sole
imaging modality throughout the entire radiotherapy pathway,
agreement in overcoming these challenges is even more critical,
as clinical teams are required to make image registration and adap-
tive planning decisions within the timeframe of a single radiother-
apy session whilst the patient remains in the treatment position. In
addition to challenges found in MR-Simulation (e.g., optimal
sequence and protocol determination for target and normal tissue
definition, quantification of geometric distortion, reproducibility of
patient positioning), sequence selection on the MR Linac (1) must
be able to be acquired and reconstructed for immediate use within
the radiotherapy pathway (for image registration and plan adapta-
tion) whilst the patient is still on the treatment bed awaiting treat-
ment delivery (2) should undergo minimal (if any) online
optimisation or manipulation to avoid invalidating geometric dis-
tortion quantifications and (3) using novel coil technology that
permits the delivery of radiotherapy beams without damaging
the electronics but may incur standoff reducing the signal-to-
noise ratio (SNR) at regions within the imaged anatomy. As such
it is important that systematic evaluations of the sequences to be
used are undertaken, to achieve the priorities of MR imaging on
the MR Linac. To this end, this work reports on the preliminaryevaluation of MR sequences following volunteer imaging on a 1.5
Tesla (T) MR Linac imaging platform using a visual grading assess-
ment (VGA), an established method for evaluating image quality in
radiography [15] which has been translated into radiotherapy [16].
Sequences were evaluated for suitability for real-time MR-CT
image registration to determine gross positional changes, as well
as for use in online re-contouring for adaptive radiotherapy by
clinical oncologist and therapeutic radiographer members of the
MR Linac team at our institution.
Materials and Methods
A Research and Ethics committee approved, four-stage non-
comparative prospective feasibility study for the development of
online MRI for magnetic resonance image guided radiotherapy
(MRIgRT) was opened at our centre in 2017. The primary aims of
the study were to develop generalised MR Linac based image
sequences and imaging suitable for normal tissue and target visu-
alisation and to be used for MRIgRT and adaptive radiotherapy
(ART).
To evaluate the MRI sequences, the first stage of this study
invited non-patient volunteers, with no known medical issues or
MRI contraindications, to undergo up to 12 imaging sessions on
the 1.5 T MR Linac investigational device (Elekta ATL 1, Elekta
AB, Stockholm). The purpose of this stage was to review overall
MRI quality using the not yet clinical system, with a primary focus
on organs at risk within 6 anatomical regions. Normal tissue visu-
alisation and the ability to contour them, is a very important part
of on-line adaptive radiotherapy, as organs at risk (OARs) may well
be the dose limiting structures in the delivery of radiotherapy. Fur-
ther stages of the study (subject of on-going work) will include
patient volunteers and focus on treatment targets.
Study information sheets were sent to volunteers and after
providing written informed consent, volunteers completed an
A. ABDOMEN
T1 3D mDIXON TFE T2 TSE MV*
B. FEMALE PELVIS
T2 3D TSE
Fig. 1. Example plot of anatomy evaluation for the most frequently acquired sequences reviewed for all patients by three observers for each volunteer, showing proportion of
evaluation results as very clear, clear, unclear or not visible. *preferred sequence.
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the study team. The total number of volunteers was designed
to be dependent on the ability to optimise imaging protocolsand the number of repeat imaging sessions volunteers were
willing to undergo. As imaging would be concluded for each
body region, acceptable protocols were developed for a cohort
C. MALE PELVIS
T2 3D TSE T2 TSE MV* 
D. THORAX – CHESTWALL/BREAST
T1 3D mDIXON TFE* T2 TSE MV
Fig. 1 (continued)
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from 18-54 volunteers (minimum of 3 and maximum of 9 vol-
unteers per anatomical region), for 6 anatomical regions. Forvolunteers undergoing more than one imaging session, MR
Safety was re-confirmed by a study team member at each
session.
E. THORAX - LUNG/OESOPHAGUS
T1 3D mDIXON TFE* T2 noFS 2D TRIGGER NAV
  F. HEAD AND NECK 
T1 3D mDIXON TFE T2 TSE MV* 
Fig. 1 (continued)
60 C.L. Eccles et al. / Technical Innovations & Patient Support in Radiation Oncology 12 (2019) 56–63Participant recruitment was staggered into cohorts of 3 patients
per anatomical region which included the male pelvis, female pel-
vis, thorax, abdomen and head and neck. The thorax region wasfurther sub-divided into lung/oesophagus and breast/chest wall
due to the specific imaging needs of these particular tumour sites
for a later stage of the study.
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patient immobilisation devices, to mimic treatment positions for
the body region being imaged. A maximum of 60 minutes on-
table time was allowed and volunteers were invited to complete
an experience questionnaire at the end of each session. The ques-
tionnaire asked for feedback on the tolerability of the MR Linac
scan, namely how anxious was the volunteer before and after the
scan, and did the volunteer experience any dizziness, discomfort,
tingling or heating. Volunteers were imaged using a pre-defined
set of sequences making up a protocol (or ‘examcard’) best thought
to demonstrate normal tissues within the anatomical region being
reviewed. Each sequence was acquired over 2–7 minutes using
vendor-specific geometric distortion correction. The protocols
included a combination of mDixon, 2D, 3D, T1w and T2w
sequences (Table 1). The motivation for the initial sequence selec-
tion was based on:
1. Manufacturers provided proposed T1 and T2 sequences on the
pre-clinical system. These were the first sequences used.
2. Sequences used as part of MR Simulation (using a different
manufacturer’s magnet), translated for evaluation to MR Linac
system.
Images were acquired and modified iteratively whenever
sequences were determined to be unsuitable (i.e. the majority of
relevant tissues were deemed unclear or not visible by a majority
of observers). Recruitment continued until imaging from a mini-
mum of three consecutive non-patient volunteers using the same
protocol were deemed acceptable for normal tissue visualisation
for each anatomical region and to be used for the next stage of
the study, with patient volunteers.
The structures reviewed related to tumour sites anticipated to
be treated (Table 2). The images from each session were reviewed
by a panel of 3 observers (a clinical oncologist, a therapeutic radio-
grapher and one other MR Linac-based researcher) with the view
to being used within a particular patient population so therefore,
some sequences were reviewed by multiple panels. For example,
images acquired of the male pelvis were reviewed by prostate,
bladder, and rectal cancer observer panels; the abdominal images
were reviewed by observers with a view to use in hepatobiliary-
pancreatic (HBP) and paediatric radiotherapy and images of the
female pelvis were reviewed with a view to treating cervix, bladderFig. 2. Representative single slice (axial) views of the preferred sequences for each a
Oesophagus, C T2 3D TSE Female Pelvis, D T2 TSE MV Head and Neck, E T1 3D mDIXONand rectal cancers. In total, there were 10 ‘review panels’, each
formed of 3 observers. The multi-disciplinary teams provided con-
sensus to determine the ‘preferred’ sequences, as it was important
that all end-users were in agreement moving forward.
Images were reviewed in isolation and with no reference image
therefore individual structures were reviewed using an absolute
VGA [17]. The VGA scale had four grades which were ‘‘very clear”,
‘‘clear”, ‘‘unclear” and ‘‘not visible”. For each image a list of struc-
tures was provided by the clinical oncologist, which would typi-
cally be contoured as a target volume or organ at risk in
radiotherapy planning e.g. prostate, seminal vesicles, rectum, blad-
der, bowel.Results
Between October 2017 and February 2018, 31 imaging sessions
were undertaken in 26 volunteers. Images were acquired each ses-
sion in one or two of six general anatomical regions: male pelvis
(n = 9), female pelvis (n = 4), chestwall/breast (n = 5), lung/oesoph-
agus (n = 5), abdomen (n = 3) and head and neck (n = 5). Each
imaging session included an average of six sequences (range 2–
10), with a maximum scan time of approximately one hour.
Volunteers ranged in age from 22-61 years and included 11
men and 15 women. A validated experience questionnaire assess-
ing tolerability of the MR Linac scan, namely how anxious was the
volunteer before and after the scan, and did the volunteer experi-
ence any dizziness, discomfort, tingling or heating, was provided.
Imaging was reported to be well tolerated, with only three sessions
requiring early termination due to positional discomfort. Full
results of the experience study will be presented elsewhere. To
address the reported discomfort, shorter scan times and position
optimisation are being considered.
Overall, 23 observers participated in the sequence selection,
including five therapeutic radiographers, ten consultant clinical
oncologists and eight clinical oncology research fellows.
The preferred sequences for each treatment site were deter-
mined based on the frequency with which all (or most) of the
organs at risk were graded as ‘clear’ or ‘very clear’. Figs. 1A to 1F
are a representative example of the results of sequence selection
to demonstrate the proportion of observers selecting ‘clear’ or ‘very
clear’ versus ‘unclear’ or ‘not visible’ for anatomy reviewed.natomical region. Legend: A T2 TSE MV Abdomen, B T1 3D mDIXON TFE Lung/
TFE BREAST/thorax F. T2 TSE MV Male Pelvis.
Table 3
Preferred imaging sequence details by anatomical region.
Anatomical Region Preferred Sequence
Male Pelvis T2 TSE MV
Female Pelvis T2 3D TSE
Abdomen T2 TSE MV
Chestwall/Breast T1 3D mDIXON TFE
Lung/Oesophagus T1 3D mDIXON TFE
Head and Neck T2 TSE MV
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sites except the chestwall/breast and lung/oesophagus (Table 3).
The T1 3D mDIXON TFE was the preferred sequence in the thorax
region. Three teams (lung/oesophagus, female pelvis, chestwall/
breast) selected the volumetrically acquired sequences as their
preferred images, and the remaining three teams selected the T2
TSE MV (multivane). By the end of this process, treatment sites
had agreed on at least one suitable sequence to be evaluated in
patient volunteers.
Discussion
To our knowledge this is the first report of a systematic selec-
tion of sequences for the use of on-board MRI guided radiotherapy
undertaken in non-patient volunteers. A strength of this study is
that all observers were end-users, (i.e., clinical oncologists and
therapeutic radiographers) with requirement for image interpreta-
tion in their respective roles to deliver MRIgRT.
T2w images were preferred in the abdomen, pelvis and head
and neck anatomical regions. T1w sequences were preferred in
the thorax. All of the preferred sequences in this study demon-
strated qualities desirable for on-treatment position verification
and re-planning MRIgRT, specifically, sufficient signal to noise
ratios (SNR) providing contrast suitable for rapid image interpreta-
tion [18,19,13]. Volumetric image acquisitions offer advantages in
this area as they are based on the excitation of the entire imaging
volume, with additional phase encoding along the slice directions
to generate 3D images without gaps, as often found in 2D acquisi-
tions acquired in diagnostic imaging. Another advantage of 3D
image acquisitions is the improved SNR because this is related to
the number of phase encoding steps, and the signal is acquired
over the entire volume [20].
With the exception of the thoracic anatomical regions (lung/
oesophagus and chestwall/breast), the majority of preferred
sequences were T2w, which is consistent with the generalisation
that T1w images are considered best suited for visualisation of
gross structural information (i.e., anatomy) and T2w images for
biological characteristics that may aid identifying pathological
information [14,21]. MRI acquisition is slow when compared to
CT, and T2w spin echo sequence acquisitions are inherently slower
the T1w gradient echo acquisitions due in part to their long repe-
tition times (TR). In the context of on-board imaging for radiother-
apy patient positioning and adaptive treatment planning, it is
important to exploit any and all techniques to achieve the fastest
acquisition possible with minimal geometric distortion. Turbo spin
echo (TSE) or fast spin echo (FSE) used in this work are known to be
able to speed up T2 weighted image acquisitions significantly,
reducing image acquisition times. The ability of the TSE sequence
to use the interval time after the first echo to receive the echo train,
filling k-space quickly also makes TSE image acquisitions less sen-
sitive to motion. Another preferred T2w acquisition was the multi-
vane (MV) sequence. This is a fast-imaging tool that uses a radial
sampling technique to reduce motion sensitivity and aliasing arti-
facts, by leveraging vendor-specific parallel imaging techniques
[22].In the thorax, observers preferred T1w mDIXON sequences. The
mDIXON is a multi-echo sequence that provides images in and out
of phase, as well as water and fat saturated weightings. The in-
phase T1w component of the mDIXON sequence looks most similar
to the planning CT in terms of image contrast and therefore makes
image interpretation for registration with the planning CT straight-
forward. Another advantage is that this is the same type of
sequence that is used for MRI-only planning products by commer-
cial partners (Koninklijke Philips NV) [23,24]. In future, it is antic-
ipated that using consistent imaging contrasts across radiotherapy
planning, in-room positional imaging and adaptation will not only
minimise inter-observer image registration variation, but also
facilitate rapid online registrations.
This early experience with MRI sequence evaluation on the MR
Linac has demonstrated the feasibility of multi-disciplinary obser-
ver image interpretation and agreement in sequence selection for
MRIgRT and ART. It is anticipated that when imaging patients the
use of functional imaging will result not only in different weighting
preferences, but also in additional challenges, for example reduced
geometric fidelity when using parallel imaging techniques. As such
it would be recommended that the implementation of more
sophisticated imaging techniques adhere to the recommended
characteristics by Paulson et al [13] and undergo a similar system-
atic review for selection.
This study did not evaluate inter-observer registration or seg-
mentation using these images however, work in those areas is
on-going for example in the prostate [25]. This study is currently
being opened at a second institution, the results of which will be
compared to these preliminary outcomes.
The results presented here are from the first stage (Stage A) of a
four-stage trial (PRIMER) which aims to optimise protocols (exam-
cards) on the MR Linac for normal tissue and tumour visualisation
during radiotherapy. The purpose of Stage A was to evaluate
whether normal anatomical structures could be visualised on this
novel technology, having not been used in the clinical setting at
the time of recruitment. The technology differs from a standard
diagnostic MRI by having a magnet modified to allow the insertion
of a rotational linear accelerator gantry [26]. Image acquisition on
non-patient volunteers allowed the researchers to build confidence
with using the system as preparatory work for moving onto patient
volunteer image evaluation in Stage B of the PRIMER trial. Stage B
will focus on target and OAR visualisation for specific tumour types
using sequences selected as optimal in Stage A for normal tissue.
These sequences will be acquired in patient volunteers and follow
the same VGA as Stage A. Sequences may then be adapted to
enhance visualisation of the treatment target if necessary.Conclusion
This work has facilitated the selection of agreed exam cards for
evaluation in patients both from the perspective of MRIgRT appro-
priateness (i.e., selecting from high resolution, geometrically
robust images) and interdisciplinary agreement on the sequences
that will meet the requirements of MRIgRT and ART at our
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